投资银行Piper Sandler宣布将enGene Holdings Inc的股票评级从"增持"下调至"中性"，同时将其目标股价从7美元大幅调降至4美元。此次评级调整反映出该机构对这家生物技术公司短期前景的谨慎态度。
分析师在最新报告中指出，尽管enGene在基因治疗领域拥有独特技术平台，但近期临床进展和商业化时间表存在不确定性。目标价的大幅下调主要基于对研发里程碑达成周期的重新评估，以及当前生物科技板块的整体估值压力。
市场数据显示，此次评级调整后，enGene股价可能面临新的下行压力。该股今年以来已累计下跌约35%，表现逊于同行业多数竞争对手。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.